Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $476.00 | 1 | 86.7% |
| Food and Beverage | $73.19 | 5 | 13.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $476.00 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $29.91 | 2 | $0 (2017) |
| Allergan Inc. | $17.02 | 1 | $0 (2017) |
| INSYS Therapeutics Inc | $15.26 | 1 | $0 (2017) |
| TESARO, Inc. | $11.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $476.00 | 1 | Celgene Corporation ($476.00) |
| 2017 | $73.19 | 5 | Novartis Pharmaceuticals Corporation ($29.91) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/01/2019 | Celgene Corporation | CC-486 (Drug) | — | In-kind items and services | $476.00 | Research |
| Study: A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects (CC-486-CAGEN-001) | ||||||
| 11/14/2017 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $20.31 | General |
| 10/17/2017 | Novartis Pharmaceuticals Corporation | SANDOSTATIN LAR (Drug) | Food and Beverage | In-kind items and services | $9.60 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2017 | Allergan Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: CYSTIC FIBROSIS | ||||||
| 05/09/2017 | TESARO, Inc. | VARUBI (Drug), ZEJULA | Food and Beverage | In-kind items and services | $11.00 | General |
| Category: ONCOLOGY | ||||||
| 01/31/2017 | INSYS Therapeutics Inc | SUBSYS (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: Breakthrough Cancer Pain | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects (CC-486-CAGEN-001) | Celgene Corporation | $476.00 | 1 |
About Dr. Vivek Khemka, MD
Dr. Vivek Khemka, MD is a Hematology & Oncology healthcare provider based in Goodyear, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1073792289.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vivek Khemka, MD has received a total of $549.19 in payments from pharmaceutical and medical device companies, with $476.00 received in 2019. These payments were reported across 6 transactions from 5 companies. The most common payment nature is "" ($476.00).
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Goodyear, AZ
- Active Since 10/24/2007
- Last Updated 04/14/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1073792289
Products in Payments
- CC-486 (Drug) $476.00
- ZENPEP (Drug) $17.02
- SUBSYS (Drug) $15.26
- VARUBI (Drug) $11.00
- SANDOSTATIN LAR (Drug) $9.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Goodyear
Govardhanan Nagaiah, Md, MD
Hematology & Oncology — Payments: $265,144
Dr. Jeremy Larsen, Md, MD
Hematology & Oncology — Payments: $98,026
Dr. Cynthia Lynch, M.d, M.D
Hematology & Oncology — Payments: $7,340
Firas Shadad, Md, MD
Hematology & Oncology — Payments: $5,273
Robert Whitehead, Md, MD
Hematology & Oncology — Payments: $225.90
Richard Shildt, M.d, M.D
Hematology & Oncology — Payments: $118.85